COVID-19 and Diabetic Nephropathy

Abstract

Diabetic nephropathy is the most common condition that requires a chronic renal replacement therapy, such as hemodialysis, peritoneal dialysis, kidney transplantation, or simultaneous kidney-pancreas transplantation. Chronic kidney disease progression, that is the loss of nephrons, which causes the continuous decline of the eGFR, underlies the pathogenesis of diabetic nephropathy. During the COVID-19 pandemic, it became clear that diabetic nephropathy is amongst the independent risk factors that predicts unfavourable outcome upon SARS-CoV2 infection. While we still lack conclusive mechanistic insights into how nephrons are rapidly lost upon SARS-CoV2 infection and why patients with diabetic nephropathy are more susceptible to severe outcomes upon SARS-CoV2 infection, here, we discuss several aspects of the interface of COVID-19 with diabetic nephropathy. We identify the shortage of reliable rodent models of diabetic nephropathy, limited treatment options for human diabetic nephropathy and the lack of knowledge about virus-induced signalling pathways of regulated necrosis, such as necroptosis, as key factors that explain our failure to understand this system. Finally, we focus on immunosuppressed patients and discuss vaccination efficacy in these and diabetic patients. We conclude that more basic science and mechanistic understanding will be required both in diabetic nephropathy as well as in host immune responses to the SARS-CoV2 virus if novel therapeutic strategies are desired.

Key words

diabetic nephropathy - diabetes - chronic kidney disease - COVID19 - necroptosis

Publication History

Received: 01 March 2022

Accepted after revision: 06 April 2022

Accepted Manuscript online:
06 April 2022

Article published online:
11 May 2022

• References

• 1 Romagnani P, Remuzzi G, Glassock R. et al. Chronic kidney disease. Nat Rev Disease Primers 2017; 3: 17088
• 2 Ruiz-Ortega M, Rayego-Mateos S, Lamas S. et al. Targeting the progression of chronic kidney disease. Nat Rev Nephrol 2020; 16: 269-288
• 3 Venkatachalam MA, Weinberg JM, Kriz W. et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 2015; 26: 1765-1776
• 4 Tervaert TW, Mooyaart AL, Amann K. et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563
• 5 Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67: 404-419
• 6 Maremonti F, Meyer C, Linkermann A. Mechanisms and models of kidney tubular necrosis and nephron loss. J Am Soc Nephrol 2022; 33: 472-486
• 7 Schreiber A, Rousselle A, Becker JU. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc Natl Acad Sci U S A 2017; 114: E9618-E9625
• 8 Campbell RC, Ruggenenti P, Remuzzi G. Proteinuria in diabetic nephropathy: treatment and evolution. Curr Diabetes Rep 2003; 3: 497-504
• 9 Yamanouchi M, Furuichi K, Hoshino J. et al. Nonproteinuric diabetic kidney disease. Clin Exp Nephrol 2020; 24: 573-581
• 10 Rivero J, Merino-López M, Olmedo R. et al. Association between postmortem kidney biopsy findings and acute kidney injury from patients with SARS-CoV-2 (COVID-19). Clin J Am Soc Nephrol 2021; 16: 685-693
• 11 Nadim MK, Forni LG, Mehta RL. et al. COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) workgroup. Nat Rev Nephrol 2020; 16: 747-764
• 12 Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. Nat Rev Nephrol 2018; 14: 48-56
• 13 Herbach N, Schairer I, Blutke A. et al. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal Physiol 2009; 296: F819-F829
• 14 Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (London, England: 1979) 2013; 124: 139-152
• 15 Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol 2017; 13: 311-318
• 16 Steenblock C, Schwarz PEH, Ludwig B. et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 2021; 9: 786-798
• 17 Braun F, Huber TB, Puelles VG. Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far?. Kidney Int 2020; 98: 10921094
• 18 Braun F, Lütgehetmann M, Pfefferle S. et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet (London, England) 2020; 396: 597-598
• 19 Steenblock C, Richter S, Berger I. et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun 2021; 12: 3534
• 20 Belavgeni A, Meyer C, Stumpf J. et al. Ferroptosis and necroptosis in the kidney. Cell Chem Biol 2020; 27: 448-462
• 21 Linkermann A, Green DR. Necroptosis. N Eng J Med 2014; 370: 455-465
• 22 Xu G, Li Y, Zhang S. et al. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res 2021; 31: 1230-1243
• 23 Silvagno F, Vernone A, Pescarmona GP. The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants (Basel, Switzerland) 2020; 9(7): 624
• 24 von Mässenhausen A, Zamora Gonzalez N, Maremonti F. et al. Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion. Sci Adv 2022; 8: eabl8920
• 25 Fried LF, Emanuele N, Zhang JH. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Eng J Med 2013; 369: 1892-1903
• 26 Menon R, Otto EA, Sealfon R. et al. SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. Kidney Int 2020; 98: 1502-1518
• 27 Janssen O, Qian J, Linkermann A. et al. CD95 ligand – death factor and costimulatory molecule?. Cell Death Different 2003; 10: 1215-1225
• 28 Linkermann A, Qian J, Janssen O. Slowly getting a clue on CD95 ligand biology. BiochemPharmacol 2003; 66: 1417-1426
• 29 Lettau M, Pieper J, Gerneth A. et al. The adapter protein Nck: role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Protein Sci 2010; 19: 658-669
• 30 Boldin MP, Goncharov TM, Goltsev YV. et al. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-815
• 31 Ko GJ, Jang HR, Huang Y. et al. Blocking Fas ligand on leukocytes attenuates kidney ischemia-reperfusion injury. J Am Soc Nephrol 2011; 22: 732-742
• 32 Linkermann A, Himmerkus N, Rolver L. et al. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int 2011; 79: 169-178
• 33 Gong Y-N, Guy C, Olauson H. et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 2017; 169: 286-300.e216
• 34 LaRocca TJ, Sosunov SA, Shakerley NL. et al. Hyperglycemic conditions prime cells for RIP1-dependent necroptosis. J Biol Chem 2016; 291: 13753-13761
• 35 Degterev A, Linkermann A. Generation of small molecules to interfere with regulated necrosis. Cell Mol Life Sci 2016; 73: 2251-2267
• 36 Hildebrand JM, Lo B, Tomei S. et al. A family harboring an MLKL loss of function variant implicates impaired necroptosis in diabetes. Cell Death Disease 2021; 12: 345
• 37 Budde K, Becker T, Arns W. et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet (London, England) 2011; 377: 837-847
• 38 Nagib AM, Elsayed Matter Y, Gheith OA. et al. Diabetic nephropathy following posttransplant diabetes mellitus. Exp Clin Transplant 2019; 17: 138-146
• 39 Akalin E, Azzi Y, Bartash R. et al. Covid-19 and kidney transplantation. N Eng J Med 2020; 382: 2475-2477
• 40 Babel N, Anft M, Blazquez-Navarro A. et al. Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. Am J Transplant 2020; 20: 3210-3215
• 41 Suwanwongse K, Shabarek N. Fatal outcome in a kidney-pancreas transplant recipient with COVID-19. Cureus 2020; 12: e8691
• 42 Westhoff TH, Seibert FS, Bauer F. et al. Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient. Am J Transplant 2020; 20: 3216-3220
• 43 Stumpf J, Siepmann T, Lindner T. et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Regional Health Europe 2021; 9: 100178
• 44 Karki R, Sharma BR, Tuladhar S. et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 2021; 184: 149-168.e117